Influence of non-alcoholic fatty liver disease on cardiovascular risk in patients with stable coronary heart disease

The objective of the research was to evaluate the effectiveness of long-term antiplatelet and hepatoprotective differentiation therapy in patients with postinfarction cardiosclerosis and co-existent non-alcoholic fatty liver disease in stage of steatosis.Materials and methods. There were examined 72 patients with stable coronary heart disease functional classes II-III and co-existent non-alcoholic fatty liver disease in stage of steatosis. All the patients underwent a complete clinical examination; the functional state of their liver and platelet haemostasis were assessed. All patients received standard therapy the effectiveness of which was assessed 3 and 6 months after treatment.Results. The effectiveness of antiplatelet therapy was found to depend on treatment duration, the functional state of the liver and the scheme of antiplatelet and hepatoprotective differentiation therapy. In particular, 6 months after treatment, a positive dynamics of platelet haemostasis was observed in all the patients of Group I. However, the target value of its indicators was achieved in 60.5% of patients. In Group II, the target level of platelet aggregation activity was achieved in 38.3% of patients. The level of liver enzymes was within the control limits in 52.8% of patients. In 47.2% of patients, however, an increase in their level was observed, which necessitated the administration of appropriate hepatoprotective therapy.Conclusions. The developed concept of differentiation treatment of patients with coronary heart disease and co-existent non-alcoholic fatty liver disease in stage of steatosis envisages the need for monitoring the indicators of platelet haemostasis and liver function every three months after the administration of antiplatelet therapy with the possibility of its intensification and the inclusion of hepatoprotective drugs.

Download Full-text

Prognostication of Cardiovascular Risk in Patients with Stable Coronary Heart Disease Depending on SYNTAX Score II on the Background of Nonalcoholic Fatty Liver Disease

Universal Journal of Public Health ◽

10.13189/ujph.2017.050704 ◽

2017 ◽

Vol 5 (7) ◽

pp. 362-370

Author(s):

Iryna Vakalyuk

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Cardiovascular Risk ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Syntax Score ◽

Nonalcoholic Fatty Liver ◽

Stable Coronary Heart Disease ◽

Syntax Score Ii

Download Full-text

A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Non-alcoholic Fatty Liver Disease

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2021.09.021 ◽

2021 ◽

Author(s):

Jonathan Zhi Kai Toh ◽

Xin-Hui Pan ◽

Phoebe Wen Lin Tay ◽

Cheng Han Ng ◽

Jie Ning Yong ◽

...

Keyword(s):

Risk Factors ◽

Coronary Heart Disease ◽

Heart Disease ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Meta Analysis ◽

Alcoholic Fatty Liver ◽

Global Prevalence ◽

Alcoholic Fatty Liver Disease

Download Full-text

Features of the course of gallstone disease in patients with non-alcoholic fatty liver disease

Terapevticheskii arkhiv ◽

10.26442/00403660.2020.02.000550 ◽

2020 ◽

Vol 92 (2) ◽

pp. 48-54 ◽

Cited By ~ 1

Author(s):

N. A. Cherkashchenko ◽

M. A. Livzan ◽

T. S. Krolevets

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Gallstone Disease ◽

Alcoholic Fatty Liver ◽

High Prevalence ◽

Group 3 ◽

Alcoholic Fatty Liver Disease

Aim.To update information about comorbidity of non-alcoholic fatty liver disease (NAFLD) and gallstones disease (GD), evaluation of clinical and laboratory data, including insulin, leptin and adiponectin in individuals with NAFLD in combination with GD. Materials and methods.According to the design, we conducted an open comparative study of 169 patients with NAFLD. The following comparison groups were formed: group 1 (n=95) patients with NAFLD without GD, group 2 (n=35) patients with NAFLD and GD and group 3 (n=39) patients with NAFLD, GD and previous cholecystectomy. Results.A high prevalence of coronary heart disease was found in the group of patients with GD and cholecystectomy (2=6.198,p0.05); positive, statistically significant correlation relationships of cholelithiasis, cholecystectomy with ischemic heart disease (rs=0.172,p0.05 andrs=0.241,p0.05, respectively). There was a statistically significant decrease in total bilirubin and total protein in patients of group 3 (H=7.376,p0.03 and H=6.345,p0.04). The level of leptin is statistically significantly higher and positively interrelated with cholecystectomy (H=5.812,p0.05,rs=0.313,p0.05). Conclusion.Patients with NAFLD, GD and previous cholecystectomy have a high prevalence of coronary heart disease; the phenomenon of insulin and leptin resistance, high level of adiponectin were revealed in patients with NAFLD and gallstones; hyperleptinemia was observed among patients with NAFLD, GD after cholecystectomy.

Download Full-text

PECULIARITIES OF SYSTEMIС INFLAMMATION OF LOW INTENSITY IN PATIENTS WITH STABLE CORONARY HEART DISEASE CONCURRENT WITH NON-ALCOHOLIC FATTY LIVER DISEASE

The Medical and Ecological Problems ◽

10.31718/mep.2019.23.3-4.01 ◽

2019 ◽

Vol 23 (3-4) ◽

pp. 3-6 ◽

Cited By ~ 2

Author(s):

Yu.I. Manusha ◽

Yu.M. Kazakov ◽

Т.А. Trybrat ◽

K.E. Ischeykin

Keyword(s):

Coronary Heart Disease ◽

Heart Disease ◽

Liver Disease ◽

Endothelial Dysfunction ◽

Fatty Liver ◽

Systemic Inflammation ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Low Intensity ◽

Alcoholic Fatty Liver Disease

Nowadays, coronary heart disease and non-alchoholic fatty liver disease are significant problems in Ukraine and world. Functional liver disorders potentiate the development and progression of CHD. The initiation process of atherosclerosis is a chronic systemic inflammation of low intensity. This view on atherosclerosis development has been forming during the past two decades. The aim of the research was to study the features/characteristics of systemic inflammation of low intensity in patients with coronary heart disease in combination with non-alcoholic fatty liver disease. The research involved 135 people with CHD: stable angina, I-II functional class, 0-I heart failure in combination with non-alcoholic fatty liver disease and 30 healthy individuals. We examined patients in terms of blood levels of cytokines -TNFα and IL-10, the content of the acute phase reactant and the coagulation factor, the marker of endothelial dysfunction is the amount of circulating endothelial microparticles (CEM) CD32+ CD40+ and the expression level of IkBα gene NF-kB in mononuclear peripheral blood. We studied the level of expression of the mRNA gene of IkBα in mononuclear cells, which reflects the level of transcriptional activity of NF-kB in patients with stable coronary artery disease and CHD in combination with NAFLD showed a significant increase in the expression of the mRNA gene of IkBα by 88.5% compared to patients with stable stable coronary heart disease. The analysis of the functional state of the endothelium with help of CEM CD32+ CD40+ has shown the presence of endothelial dysfunction in the groups of patients with CHD and CHD in combination with of NAFLD. Comparison of the indicators of systemic inflammation of low intensity and marker of endothelial dysfunction in patients with CHD in combination with NAFLD revealed a significant increase of TNFα, acute phase reactant and coagulation fibrinogen factor and expression of the mRNA IkBα gene in patients with comorbidity, indicating an increase the level of systemic inflammation of low intensity in patients with CHD in combination with NAFLD as compared with the group of patients with CHD.

Download Full-text